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Abstract
Introduction: Inadequate access to essential medicines is a common issue within developing countries. Policy response is
constrained, amongst other factors, by a dearth of in-depth country level evidence. We share here i) gaps related to access
to essential medicine in Pakistan; and ii) prioritization of emerging policy and research concerns.
Methods: An exploratory research was carried out using a health systems perspective and applying the WHO Framework for
Equitable Access to Essential Medicine. Methods involved key informant interviews with policy makers, providers, industry,
NGOs, experts and development partners, review of published and grey literature, and consultative prioritization in
stakeholder’s Roundtable.
Findings: A synthesis of evidence found major gaps in essential medicine access in Pakistan driven by weaknesses in the
health care system as well as weak pharmaceutical regulation. 7 major policy concerns and 11 emerging research concerns
were identified through consultative Roundtable. These related to weaknesses in medicine registration and quality
assurance systems, unclear and counterproductive pricing policies, irrational prescribing and sub-optimal drug availability.
Available research, both locally and globally, fails to target most of the identified policy concerns, tending to concentrate on
irrational prescriptions. It overlooks trans-disciplinary areas of policy effectiveness surveillance, consumer behavior,
operational pilots and pricing interventions review.
Conclusion: Experience from Pakistan shows that policy concerns related to essential medicine access need integrated
responses across various components of the health systems, are poorly addressed by existing evidence, and require an
expanded health systems research agenda.
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Introduction
Essential medicines, as defined by World Health Organization
(WHO), are those that satisfy the health care needs of majority of
the population. Support for access to essential medicines is pledged
under Millennium Development Goal 8 and the provision of
affordable, high quality and appropriate essential medicines is a
component of functioning health systems [1]. However access to
essential medicines in low and middle income countries (LMICs)
remains questionable [2]. Cohesive evidence is essential to
understanding, planning, monitoring and evaluating access to
medicines [3].
There are a number of gaps related to evidence on access to
essential medicines. First, although reasonably sufficient informa-
tion from the Organization for Economic Co-operation and
Development (OECD) countries is available on essential medicine
access, the data from LMICs is often weak, fragmented and
requires collation [2]. Second, even where published research on
medicines is available in LMICs the evidence has usually not been
well integrated the within wider health systems responses and the
pharmaceutical and health systems stakeholders continue to
function in silos. A health systems perspective applying health
policy and system research frameworks (HPSR) is hence needed in
the generation of evidence on access to essential medicines [4].
Third, ideally, such country case studies need to go beyond
empirical data collection to also include consultation of local
stakeholders in the generation of prioritized policy and research
concerns. Prioritization of policy and research areas has been
typically driven from the global level and more recently there has
been a call for country level iterative priority setting exercises
involving a range of stakeholders, so as to come up with more
context specific and nationally driven policy and research concerns
for improved health systems [5].
This paper attempts to add to the global evidence on access to
essential medicines by sharing findings from Pakistan. It applies
both a health systems perspective and a local priority setting
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exercise. The paper sets out to i) identify policy concerns in access
to medicines through desk review and key informant interviews;
and ii) present consultatively prioritized policy and research
concerns. The results are intended to improve the use of evidence
in medicines policies and forging integrated responses to related
challenges within the heath systems.
Setting
Pakistan has a population of 185 million, a Gross National
Product (GNP) per capita of $1200 and a literacy rate of 53
percent [6]. Pakistan has a mixed health care system with the
public sector providing services to 22 percent of population and a
dominant private sector, mainly comprising of private for profit
practitioners and health facilities, serving the rest of the
population. The Drug Control Organization located until recently
within the federal Ministry of Health (MOH) has been responsible
for producer licensing, drug testing, drug registration, pricing and
trade, while Drug Quality Control Boards located within the
provincial Departments of Health (DOH) are responsible for
market surveillance. Under a constitutional amendment in the
MOH along with a number of other social sector ministries was
devolved in 2011 to the provinces and the re-organization of drug
regulation is unclear. The Pakistan Medical and Dental Council
and the Pakistan Pharmacy Council are responsible for licensing
medical and pharmacy schools and practitioners. The Pakistan
Medical Association and the Pakistan Pharmacists Association
represent the interests of the two main provider groups. The
Pakistan Pharma Bureau represents the local industry and forms
an active interface for dealings with the government on drug
production, pricing and trade.
Access to essential medicines, as part of the fulfillment of the
right, to health is recognized in the national constitution. Pakistan
has fairly well developed policy acts and operative guidelines. The
Drug Act 1976 regulates the pharmaceutical sector setting out
extensive stipulations for industry licensing, drug registration and
quality control. The Drug Act of Pakistan has neither been
updated with the international the World Trade Organization’s
(WTO) statutes nor with local stipulations such as the Pakistan’s
Patent Ordinance of 2000. A National Medicines Policy was
developed in 1993 and again in 1997, but do not have a strategic
plan for implementation.
Methods
Ethics Statement
Ethical approval of the Aga Khan University Ethics Review
Committee was obtained prior to start of the study. Written
informed consent was obtained from each interviewee. Confiden-
tiality of identity was maintained in the analysis and write-up by
replacing interviewee identity with a code.
Approach and Framework
The Pakistan Access to Medicines (ATM) priority setting study
was part of a larger global study involving 17 countries over five
regions and formed the Easter Mediterranean Regional (EMR)
sub-set together with Iran and Lebanon. An exploratory policy
analysis was conducted using the WHO Framework for Equitable
Access to Essential Medicine [7] as the conceptual basis for data
collection and synthesis (Figure 1). Under this framework
accessibility has been defined as having four parameters: that i)
there are reliable health systems for ensuring medicines are
available and effective, ii) affordable pricing, iii) sufficient health
financing to remove financial barriers for patients, and iv) that
required knowledge and guidance are available for rational use of
these medicines. It assumes that isolated efforts to improve one
aspect might not ensure adequacy of access to essential medicines.
We gathered data from desk reviews and stakeholder interviews
followed by a stakeholder roundtable to prioritize the emerging
policy and research concerns. The desk review and fieldwork was
carried out during January to May 2011 and was completed just
before the devolution of the Ministry of Health in June 2011.
Desk Review
The desk review was conducted to collate primary research and
policy measures. Electronic database search of peer reviewed and
grey literature was conducted by 2 researchers using Medical
Subject Headings (MESH) terms (Table 1), and complemented by
a hand search of bibliography. Primary research and reviews were
included while commentaries and bio-efficacy studies were
excluded. Study design filters were not applied to the primary
research reviewed as the purpose was to obtain an overview of
evidence rather than conduction of a systematic review. The
MESH words used singly and in combination yielded 2176 titles
that were further sifted to shortlist appropriate abstracts for review.
A total of 184 abstracts were retrieved and reviewed, and
shortlisted to 68 full text studies. The search was conducted by 2
researchers with Researcher 1 conducting the initial screening of
titles and abstracts, while Researcher 2 reviewed the title and
abstracts search, and consensus was reached between the two
researchers on selection of relevant articles. All selected articles
were independently reviewed by both the researchers. In addition,
19 policy documents were also identified, 14 through the online
search and 5 during the course of stakeholder interviews.
Information was extracted into thematic grids and organized
under the four domains on the WHO Equitable Access to
Essential Medicines Framework. Researcher 1 did the initial
extraction, while Researcher 2 reviewed the extraction, and any
disagreement was resolved through combined review of the article
by both researchers and arriving at a consensus.
Key Informant Interviews
Through consultation amongst the regional study teams of
Pakistan, Iran and Lebanon a listing of stakeholder categories was
developed so as to get representation from diverse stakeholders
and the listing comprised of the Ministry of Heath, Departments of
Health, Industry, Researchers, Development Partners, Advocates,
Clinicians, Pharmacists and Private Providers (Table 1). Stake-
holders within each listed category were identified by the country
team with assistance of the WHO country office, and further
additions to the list made through a snowballing approach. A total
Figure 1. Improving Access to Essential Medicines: A Frame-
work for Collective Action.
doi:10.1371/journal.pone.0063515.g001
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of 21 interviews were conducted across the different stakeholder
categories to collect views on key issues related to access to
medicines in Pakistan and need for evidence (Table 1). Semi-
structured interviews were guided by a topic checklist, one
researcher conducted the interview while the other took notes,
and notes were manually transcribed soon after the interview.
Interviews notes were finalized after review and consensus by both
researchers. The transcripts were manually coded by Researcher 1
by organizing emerging issues under conceptual framework
themes, and the initial coding was reviewed and finalized by
Researcher 2.
Stakeholders’ Roundtable
Findings of interviews and desk review were consolidated under
the domains of the ATM conceptual framework and shared in a
Roundtable with the stakeholders (Table 1). The purpose of the
Roundtable was to share preliminary findings for validation, hear
further from the stakeholders on policy and research concerns and
undertake a consultative prioritization of the concerns highlighted
by the fieldwork and desk review. The Roundtable was attended
by 21 participants drawn from the broad range of stakeholders
interviewed (Table 1), the regional partners and WHO Alliance
Health Policy and Systems Research (HPSR).The Roundtable was
jointly moderated by Researcher 2 and a WHO representative,
and note taking done by Researcher 1 and supplemented by
Researcher 2. Validation of collected data was undertaken with
the participants reviewing the information during the Roundtable
meeting, updating information in certain areas, and pointing out
supplementary data sources. Written post hoc comments on data
validity were also invited through an email list serve and
incorporated. A focus group methodology was applied for
collective prioritization as participants opted for a consensus
building discussion to prioritize rather than quantitative scoring on
Likert scale. A moderated discussion was conducted first involving
commenting on findings by each participant followed by group
discussion on prioritization of concerns. Ranking was therefore not
attempted and instead an agreed list of concerns was developed.
Results
Desk Review
A total of 72 documents were reviewed that included 53 grey
and published studies, and 19 policy related acts, stipulations and
guidelines. English was the main language of publication and
locally produced evidence was the major source with 47 out of 53
publications from Pakistan. However studies having nationally
representative samples were few. Highest number of literature
related to rational drug use (27) with least on medicine financing
(3).
Rational Drug Use: Much known but little
action. Evidence generated by desk review largely related to
rational drug with markedly much less on other domains. Within
the rational drug use area, the major volume of research related to
prescribing practices of health care providers, there were few
studies on dispensing and community pharmacy, and no research
related to drug regulation policies and on consumer related
factors. Studies largely did not follow standardized methodologies
and lacked nationally representative samples.
Pakistan has an Essential Drug List (EDL) currently containing
335 medicines [8] and is complied by 80 percent of public sector
facilities [9]. Despite the existence of an EDL medicines have been
registered in excessive numbers comprising 1100–1200 registered
molecules and 50,000 registered drug products. Registration does
not look into comparative cost analysis over other products and
local bio-equivalency is not required [10]. The average number of
drugs prescribed per patient in Pakistan is over 3 compared to an
average of 2–3 in LMICs [2], with higher prescription of 4.5 in
Table 1. Overview of Methods.
Desk Review
Online search: Electronic databases searched:
PubMed, Cochrane, Cinahal, WHOLIS, ELDIS,
Google Scholar. Websites searched: Ministry
of Health, Provincial Departments of
Health, WHO Pakistan, WHO-EMRO and Pakistan
Consumer Protection Network.
Search Terms: Rationale Drug Use AND Pakistan;
Drug Financing AND Pakistan; Drug Affordability
AND Pakistan; Drug Access AND Pakistan;
Drug Supply AND Pakistan; Drug Availability
AND Pakistan; Drug Policy And Pakistan;
Pharmaceutical Policy AND Pakistan Searches
conducted during Jan-March 2011 and updated in
August 2012.
Research Inclusion Criteria: Primary research
studies, reviews, case reports. Excluded: opinion pieces,
commentary articles, bio-efficacy studies.
Grey Literature: Policy Acts, Policy Guidelines, Policy
or strategic frameworks, national formulary, documents
on official mandate of stakeholders.
Key Informant Interviews
Ministry of Health: Federal Directorate
HealthLicensing & Registration Board
Departments of Health Secretariat; Tertiary
Hospital; District Health Officer
Private Providers: National NGO International NGO
Dev Partners: WHO, GAVI Industry: Pakistan Pharmaceutical
Manufacturing Association
Pharmacies: Pakistan Pharmacists Association
Hospital Pharmacists Society
Researchers: Bio-Equivalence Centre, National
Health Systems Strengthening Unit
Advocates: Consumer Protection Network Clinicians: Pakistan Medical Association
Roundtable
21 Participants: Representatives from Ministry of
health, provincial Health Departments, District Health
Office, Presidents Primary Health Care Initiative, Pakistan
Pharmaceutical Manufacturing Association, Pakistan
Medical Association, Pakistan Pharmacists Association,
WHO, pharma experts, heath system experts
Sequence of Activities: Presentation of findings
Presentation of emerging concerns Validation/
correction of information through verbal adhoc and
written participant pot hoc feedback Comments
by participants on findings
Group discussion on policy concerns and prioritization
Group discussion on emerging research concerns and
priortization
doi:10.1371/journal.pone.0063515.t001
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private sector prescriptions [11], compared to 2.77 in public sector
[12]. Injection use is excessive with 60 percent of patient
encounters involving an injection [2]. Antibiotics use is also high,
more so amongst privately practicing general practitioners with 62
percent of prescriptions involving antibiotics versus 54 percent in
public sector [13]. Little difference exists between privately
practicing general practitioners and specialists in terms of excessive
antibiotic use [14]. Apart from poly-pharmacy, prescription
patterns are also inappropriate even for frontline health problems
such as tuberculosis [15], childhood diarrhea [14], acute
respiratory infection [16], hypertension [17], diabetes and
anxiety/depression [18]. Interaction of health providers with the
industry is not restricted and visit of sales representatives is linked
with increased prescription of the sponsored medications [19].
Drug dispensing time in the public sector is insufficient for patient
instruction and does not adhere to standard safety measures for
dispensing [12], however comparable figures are not available for
the private sector. Community pharmacy is also weak with little
restriction on over-the-counter medicine purchase by patients and
sub-optimal quality standards are followed with only 12 percent of
drug retail outlets having pharmacologically trained dispensers
[20] and only 19.3 percent meeting licensing requirements [21].
Self-medication of antibiotics even two decades ago ranged
between 6–8 percent in the general population [22–23] with
updated evidence likely to show higher self-use.
Affordability: Pro-poor measures but low trickle
down. The national affordability and pricing survey conducted
in 2006 [24], using WHO standardized methods provides
comprehensive information on pricing in both the public and
private sectors. Apart from this there is little research on pricing,
and no attempts at periodic updating of information.
Pro-poor measures are consciously maintained by the MOH
involving tax exemption on imported raw material and equipment
for drug manufacturing, exemption of drugs from general sales tax
and full tariff exemptions on drugs imported by United Nations
(UN) agencies and donor funded programs [25].The Drug Act
1976 is vague about pricing, and pricing is decided on case by case
basis and based largely on input cost [26]. Drug affordability
despite pricing measures continues to be a concern in Pakistan
mainly due to proliferation of originator brands and wide price
variability. Availability of basket of essential generic medicines is
low in public sector (15%) and sub-optimal even in private sector
(31%) [24].The price ratio of branded products to international
reference price ranges between 0.72 to 26.2 showing excessive
price variability while the corresponding ratio for generics is
between 0.2 and 7.02 [24].Specific medicines such as omeprazole,
ciprofloxacin and diclofenac suffer from excessive prices. Poor
drug availability in the public sector forces patients to purchase
from private retail outlets, as further discussed in the next section.
Affordability index as defined by WHO is more than 1 day’s
income by lowest paid government worker for 1 month’s standard
treatment of chronic illness or for one episode of acute illness [27].
While acute therapy using generic was found to be affordable for
acute respiratory infection at 0.3–1 days wage, therapy for chronic
illness such as hypertension, depression, diabetes, epilepsy, arthritis
and peptic ulcer is unaffordable even with use of low priced
generics at 1.7–7.7 days wage and clearly beyond reach of poor
with originator brands at 1.9–36.4 days wage [28].
Sustainable Financing: a case of low funding or inefficient
management?. In Pakistan nationally representative data is
available on medicine expenditure by the public and private
sectors from of the National Health Accounts. There are also
random studies on patient expenditure at specific health care
facilities. However, regular surveillance of medicine expenditure is
not being done although required for monitoring the results of
policy changes and of health systems innovations.
Pakistan has a total spending of USD14 per capita per year,
much below the USD 34 recommended by WHO for developing
countries, and the public sector constitutes merely 32 percent of
total health expenditure with 64 percent borne by households
mainly through out of pocket payments [29]. Medicines account
for a substantial 43 percent of total household health expenditure
in Pakistan [29]. Within the public sector only 22 percent of
operational budget is available for non-salary items including
drugs [30]. The amount expended for drugs in public sector is
below the critical threshold of $2 per capita per year recommend-
ed by the WHO to avoid medicines shortages [31]. Evidence
indicates substantial hidden cost of medicines at public sector
facilities as patients due to low drug availability are often forced to
purchase from private retail pharmacies. Mean out-of-pocket
spending per prescription is Rs.252 at private sector facilities
compared to Rs198 at public sector facilities [32].
Although experimentation with new health delivery and
financing schemes has been initiated in Pakistan involving
vouchers pilots and an extensive national contracting-in initiative
at the primary care level [33], reduction in drug expenditure is yet
to be ascertained. Zakat funds - religious welfare tax for use of
Muslims –accounts for 1 percent of total health expenditure and
are expended on drug purchase for poor patients at public sector
hospitals [29], but there has been no assessment of Zakat fund
utilization. Private philanthropies contribute towards the cost of
drugs at public sector tertiary hospitals, but these are concentrated
in urban areas, are fragmented, and have not been evaluated for
medicine access [34].
Reliable Health Systems: missing the policy
spotlight. Health systems are expected to ensure sufficient
production, quality assurance, adequate supply management of
essential medicines and appropriate human resources. Published
evidence in this area is scarce, the few studies available mainly
report on drug availability in the public sector, with little primary
research in the areas of drug procurement, logistics management,
quality assurance and sufficient production. The data sources for
these areas are mainly drawn from government records.
There has been a stride in drug production since the country’s
Independence in 1947 with currently 30 multinational and 411
local manufacturing units [25]. However self sufficiency is yet to be
achieved with only 35 percent of domestic demand met by local
manufacturing units [35] and raw material for local drug
production is almost entirely imported. Quality assurance mech-
anisms for licensing of manufacturer licensing, drug product
registration and market surveillance are well laid out by (Drug Act
1976) however the profusion of drug production outlets and drug
products raises questions about the tightness of controls. The
issuance of Statutory Regulatory Orders reportedly creates
confusion and unevenness in the application of policies [36]. At
present in Pakistan none of the manufacturing facilities are WHO
certified. Market surveillance conducted by the provincial
Departments of Health involves sampling of drugs on the market
but there still continues to be a high proportion of counterfeit
drugs [26,37]. Surveillance is restricted to drug product sampling
and overlooks quality parameters of retail outlets (Drug Act 1976).
There are frequent stock-outs of essential drugs across primary,
secondary facilities and district hospitals (34). Contracting out the
management of frontline facilities in selected districts has improved
drug availability with 22.5 percent of contracted facilities in the
highly satisfactory category for drug availability as compared to
8.3 percent of non contracted facilities [38]. Drug availability has
improved in disaster affected areas where drug distribution was
Medicine Access in Pakistan: Priority Concerns
PLOS ONE | www.plosone.org 4 May 2013 | Volume 8 | Issue 5 | e63515
managed through a network of UN agencies and international
NGOs and was linked with better inventory control and
computerized logistics support [39]. Drug storage in public sector
does not follow standard operating procedures. A survey of public
sector facilities found that the manual for procedures was available
in only 5 percent of public sector facilities, refrigerators were
working in 60 percent and temperature control was present in 24
percent [9]. Supply management in the private health sector is also
sub-optimal with available evidence indicating that only 50
percent of private facilities comply with the national EDL [11]
and merely 19 percent of drug retail outlets meet licensing
requirements [21]. Evidence for private sector is confined to small
scaled studies and needs national representative surveys.
Pharmacist availability is low across public and private sector
with only 0.06 pharmacists available per 10000 population, much
below the recommended ratio of 5 pharmacist per 10000
population [25]. Majority of pharmacists work in pharmaceutical
industry (70%), with the rest distributed over hospital pharmacy,
community pharmacy and academia [40].
Key Informant Interviews
Key informant mainly identified policy concerns as perceived by
them, with only a few respondents belonging to experts and
development partners additionally identifying research concerns.
One reason was that several of the policy concerns called for policy
actions rather than research. Another reason was that the range of
informants interviewed was not well familiar with policy related
research.
Irrational Use. ‘‘Essential generics are the gold standard but the
problem for prescribers is they have been around in the market for long time, they
don’t have star status like new brand drugs, they don’t create awe in the
market.’’ (Interview: 21/21).
Irrational drug use was thought by informants to be both widely
prevalent as well as the most complex issue. Informants stated that
prescribing practices need improvement from specialists to general
practitioners, and unauthorized prescriptions by quacks requires
regulation. Informants thought that even amongst well meaning
practitioners, generics having been around for a long time did not
enjoy the same prestige as new brand products. Frequent shortages
of low cost generics in the market further strengthen use of
irrational branded drugs. Open access of doctors to industry
representatives, lack of refresher training, demand for quick cures
by patients and entrenched parallel quackery were felt to sustain
irrational prescriptions. Similarly, little restriction over self-
medication by patients, lack of pharmacist presence at drug retail
outlets and low levels of patient awareness were felt to further
enforce irrational use.
‘‘Rational use is one of the biggest barriers in access to medicine. There are
no qualified pharmacists at the pharmacy. Then the role of marketing by
pharmaceutical companies is not ethical whereby doctors are attending
conferences in Dubai and prescribing expensive medicines and getting benefits
from these companies.’’ (Interview4/21).
At the program level, the domination of procurement by clinical
specialists, little institutional role of pharmacists in supply
management and weak enforcement of Essential Drug Lists and
available standard treatment protocols, emerged as the major
contributory factors.
At every level there should be implementation of a formulary. Institutions
should be bound to use that. Second step is protocol development. Changing
attitude of senior doctors for rational prescription and avoiding poly pharmacy is
very important.’’(Interview 18/21).
Another strong concern was an absence of tight policy levels
controls thereby resulting in excessive registration of drugs.
Stakeholders pointed to lukewarm political support for regulation
of the private sector, as evidenced by an anti-quackery bill that had
been drafted some years ago but was yet to be legislated, and little
movement by the medical community on restricting industry
access to health providers. Informants called for a multi-pronged
strategy addressing policy to consumer levels for controlling
irrational drug use.
Affordability and Pricing. ‘‘Manufacturers of drugs don’t find it
financially viable to produce thyroxine, but they prefer to make ciproxin.
Hydrochlothiazide, folic acid and primaquin and magnesium sulphate are even
not available in many of the private and public facilities.’’ (Interview:1/21).
All key informants expressed concerns related to drug afford-
ability and pricing issues. Respondents pointed to a steady
proliferation of expensive originator brands at little additional
value. For example seven different forms and prices of Acetamin-
ophen currently existed in the market. Although the Generic Drug
Act was introduced in 1972 it had to be revoked in the wake of
strong opposition by the commercial sector and the medical
community. Another concern was an absence of a clear pricing
formula as the existing pricing practice was based on reported
price of inputs. This resulted in wide price variability and was
thought to also create opportunities for collusion to obtain high
prices.
‘‘Biggest barrier to access to medicines is at the level of affordability, and my
recommendation is that Generic system of medicines should be introduced in the
country and pricing tag should be of MoH to considerably overcome issue of
affordability particularly among white collared people and poor.’’(Interview:
18/21).
Weak regulation of distribution and sale of drugs was thought to
push up the prices and the authority of Drug Inspectors to control
monitor prices was also apprehended to be weak. Yet another
concern was the flat price control in place on essential drugs since
nearly last ten years which had counter productively resulted in
the disappearance of low cost essential generics from the market
due to lack of a profit margin. Declining profits due to rising
inflationary costs was cited by the industry as one reason for low
interest in manufacturer of low priced essential drugs however the
Ministry has been reluctant to lift the price freeze due to fear of
steep increase in prices and anticipated political fallout of
inflationary medicine prices. The list of such ‘orphan drugs’
reported was alarming and included basic essentials such as
phenytoin, thiazides, adrenaline, thyroxine, primaquin, and folic
acid amongst others. The MOH’s response has been to enforce the
production of ‘orphan drugs’, which in turn has triggered sub-
standard production of essential medicines. So far differential
pricing measures have not been explored. In contrast non-essential
medicines have had periodic across the board increases and do not
face market shortages.
Financing. ‘‘Spending is low…more precisely, proper utilizations of
funds and rationalization of drugs are not done, which are mainly driven by
personal interests’’ (Interview: 2:21).
Stakeholders expressed lesser concern over adequacy of drug
financing as compared to other domains of the framework.
Opinion on drug financing was divided as to whether poor
availability of drugs in public sector is due to under-funding or
inefficient budget management.
Although public sector drug procurement involved generic
purchasing and was supposed to be efficient, however stakeholders
expressed concern on the frequent deviation from essential drug
list and replacement of generics with originator brands particularly
at hospitals which resulted in cost inefficiencies.
‘‘Problem is due more to lack of proper management of drug budget rather
than budget shortage. There is inappropriate purchasing. Although a list of 126
drugs are approved at provincial level by Secretary Health but District Health
Medicine Access in Pakistan: Priority Concerns
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Officer purchases from within this list as well as from their own wish list
leading to inappropriate purchasing and corruption.’’ (Interview 3/21).
Opportunities for collusion in procurement, drug pilferage due
to weak linkage of inventory with patient consumption, and
procurement de-linked to patient volume and morbidity data were
other issues reported and together contributed to inefficient
management of funds.
‘‘Procurement practices need to be improved, made more transparent and
competitive.’’ (Interview 16/21).
Reliable Health Systems. ‘‘An open registration policy exists in
Pakistan, every drug gets registered. More than 75000 drugs are registered, but
there is no list (of registered) drugs with the government.’’(Interview: 1/21). ‘.
Within the area of reliable health systems the strongest concerns
related to ineffective regulation of the pharmaceutical sector
followed by supply management related concerns. Stakeholders
pointed to the wide variety in quality of drug production units with
the local market ranging from sophisticated manufacturing units
having well developed quality monitoring mechanisms to low cost
units having non-existent quality assurance systems. There was felt
to be little incentive for producers to invest in quality control as
sub-standard drugs also got registered.
‘‘There is little incentive to produce well, why should industry invest in
quality assurance when others can get away with without such internal checks.’’
(Interview: 13/21).
Market surveillance was considered to be weak and attributed to
under-equipped Drug Inspectorates and their testing laboratories,
and further compounded by the excessive number of drug retail
outlets requiring. There were also concerns that low pay of drug
inspectors and high responsibilities create opportunities for
collusion with inferior suppliers and distributors. Stakeholders felt
that an absence of autonomy for the drug regulatory structure was
a major bottleneck for quality assurance and pointed to the
Supreme Court injunction in 2005 for creation of an autonomous
body which was still awaiting implementation.
‘‘We have always focused on macro-economic policies but attention to service
delivery level; has been lacking …there lies the gap.’’(Interview 5/21).
Supply management was considered by informants to be weak
but got less attention compared to regulatory concerns. Those
concerned with supply management aspects felt that it commonly
gets overlooked with policy spotlight usually on registration and
pricing issues. Stakeholders had concerns that procurement in the
public, sector despite new rules of business, favors the cheapest
bids as quality parameters for drugs are low merely requiring
registration of the drug production company. Moreover, stake-
holders expressed concern that many of the better quality
producers reportedly stay away from public sector tendering due
to low priced tenders and concerns over unreliability of
government as a payer. Drug storage and inventory management
on the other hand have more well developed standard operating
guidelines but were thought to be poorly enforced.
Low number of pharmacists in service delivery was a common
concern with most stakeholders, pointing to the meager numbers
even within large teaching hospitals, as for example only 1
pharmacist was posted in the largest Civil Hospital at Karachi with
an OPD of 800 patients/day and 1500 beds. Stakeholders called
for effective institutionalization of hospital and community
pharmacy with stronger emphasis by experts and pharmacists on
pharmacists’ roles in supply management as opposed to the
medical community.
Although not included in list of topics, the devolution of the
Health Ministry, was an area brought up by almost all informants.
Most stakeholders favored some role of the federal level in
standardizing drug licensing, registration, pricing and trade but
with allowance for increased feedback of provinces, experts,
industry and other stakeholders. Total devolution was largely felt
to create inequities in terms of drug pricing, availability and
quality across the provinces. There was concern expressed by
federal stakeholders and experts of uneven provincial capacity for
undertaking drug regulation while provincial governments felt that
inclusion of provincial voice in accountability is the major issue to
be addressed.
‘‘We are asking for a Drug Registration Authority at the federal level for
registry, pricing and trade, to be kept even after devolution of the Ministry (of
Health) to the provinces. We cannot have a drug registered in one province and
de registered in another, or charging different prices in two different provinces.’’
(Interview 13/21).
Roundtable Discussion: Prioritization of Policy Concerns
and Research Areas
Seventeen policy and 12 research concerns were shared in the
roundtable based on key areas emerging from the interviews and
desk review (Tables 2 & 3). These were prioritized and reduced
to16 policy concerns and 7 research concerns (Table 4) through a
moderated discussion, as described under Methods. Participants
agreed that access to medicines is a major issue in Pakistan and
majority of the stakeholders identified with reliable health systems
as the major area to be addressed followed by pricing and then
rational drug use. Opinion was divided over the extent of work
undertaken in this area with some expressing that substantial
policy work had been undertaken but met with varying success
while others thought that a significant policy attempt is yet to be
made.
Although ranking was not attempted, weak regulation related to
drug registration and market quality surveillance emerged as the
most critical policy concern amongst participants with a call for
better implementation of existing regulations and tightening these
in needed areas (Table 5). Next, were policy concerns related to
drug pricing and provider prescribing practices, with calls to make
more transparent pricing formula, creative pricing policy to
counter drug shortages, and multi-pronged action for irrational
drug use. This was followed by supply side concerns ranging from
budget insufficiency for drugs, procurement, storage and dispen-
sation gaps, to low deployment of pharmacists. Lack of community
level actions was raised as a concern by some participants and
there was agreement on a need for better accountability
mechanisms. Impact on essential medicines of decentralization
of health to provinces, was additionally introduced by participants
as a common concern. While participants had different views on
desirability of devolution, a consensus was reached that while a
central structure is needed to avoid inequitable drug availability
and pricing across provinces, there needs to be autonomous
functioning and greater participation of provincial government as
well as other stakeholders. The concerns expressed in the
roundtable generally conformed to the trend reported in the key
informant interviews.
Based on the prioritized policy concerns, participants identified
a range of research priorities. A need was identified for continuous
market and public sector surveillance to look into the effect of
national policies on medicine availability, prices and quality.
Other mentioned research concerns were the need for standard-
ised prescription and dispensing audits of health providers and
development of a database of private licensed providers differen-
tiating these from unlicensed and informal providers. Participants
also recommended the collation of best practice lessons on pricing
policies so as to improve access to essential generics. The need for
financing research pilots also emerged to find innovative means for
reducing medicine expenditure borne by households particularly
for chronic care therapy. Operations research for improving
Medicine Access in Pakistan: Priority Concerns
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logistics management in the public sector was also proposed
applying best practice lessons from credible NGO managed
models. Another research priority was the call for formative
research to look into consumer demand, health-seeking prefer-
ences, willingness to pay, and enhancing patient role in
accountability.
Discussion
The essential medicines area has been under-explored in health
systems research and evidence is particularly thin on country level
contextual findings from LMICs. Furthermore country level
perspective in identifying policy and research concerns has been
less well incorporated in country case studies, with medicine policy
and research driven by global priorities. We share findings from
Pakistan reporting key challenges in access to essential medicines
supplemented with a nationally driven prioritization of policy and
research concerns.
A synthesis of evidence found major gaps in essential medicine
access in Pakistan related to weak regulation of quality assurance,
poor affordability, and irrational use. These are driven both by
weaknesses in pharmaceutical regulation with little attention to
quality and cost efficiency in drug registration and a lack of
creative and transparent pricing, as well as by health systems
weaknesses involving unregulated provider prescriptions and weak
supply management.
These require cohesive policy responses involving the provision
of autonomy and capacity for drug regulation, inclusion of safety
nets such as health insurance for affordable medicine financing,
private provider regulation and community pharmacy to curtail
Table 2. Identified Policy Concerns from Desk Review and Key Informant Interviews.
Policy Program Service Provider Consumer
Irrational Use Excessive registration of drugs Procurement dominated by clinicians in
public and private sectors Purchase of
originator brands in private sector
Inappropriate prescriptions
Absence of standard
protocolsExcessive injection use
No checks at interaction with
industry
Patient demand for quick cures
Low awareness Few restrictions on
over the counter access
Pro-poor policies
but low
affordability
Flat price control Proliferation
of originator brands at
high prices Unclear pricing
formula
Market shortages of essential low cost
generics
Preference for prescribing
originator brandSwitch from
generic use to originator brand
triggered by
market shortages
Acute illness therapy affordable at
only generic prices NCD therapy
unaffordable at even generic
prices
Insufficient
Financing for
drugs
Insufficient public sector
spending on health
Health budgets dominated by salaries
Health equity funds: sporadic and
unmonitored useLack of alternative
financing models having drug subsidies
Drug stock-outs in public sector
Improved drug availability with
contracting out but questionable
quality Prescription of originator
brands in private sector
Highest OOP share spent on
medicines OOP on medicines
incurred at both private and public
sector
Weak Health
Systems
Drug production reliance on
both local and multinational
companiesLow quality threshold
for drug registration Fragmented
mandate for pharma policy across
federal and provincial levels in post
devolution context
Counterfeit medicines but insufficient
resources for market surveillance Cost
efficiency but low quality in drug
procurement: public sector Lack of
adherence to national formulary: private
sector Insufficient production and
deployment of pharmacists Weak logistic
management and information systems
Inadequate dispensing
skillsWeakness in drug
storageProliferation of shadow
pharmacies
Social accountability mechanisms
needed
doi:10.1371/journal.pone.0063515.t002
Table 3. Identified Research Concerns from Desk Review and Key Informant Interviews.
Research Concerns:
1. Impact of decentralization on prices, availability and access
2. Determinants underlying weak implementation of existing medicines policies
3. Decision making role of pharmacists for medicine supply management
4. How to improve pricing policies for better access to essential generic drugs
5. Role of private sector particularly shadow pharmacies in drug prescription, stocking and dispensation
6. Post-marketing assessment of drug quality
7. Information, availability and transparency in public domain
8. Operational research for development of a medicines information system
9. Consumer Health seeking preferences and underlying determinants
10. Monitoring of market medicine price to inform pricing regulations
11. Unit cost estimation for optimal pricing of drugs
12. Transparent information on registered drugs and prices for public consumption
doi:10.1371/journal.pone.0063515.t003
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excessive prescription, and use of more methodical procurement
practices.
Similar priority setting exercises have been recently conducted
in 16 other LMICs. Pakistan in contrast to other countries has
higher concerns related to drug quality regulation and reliable
health systems, but shares medicine pricing and rational use
concerns with a number of other countries. Affordability and
financing dominate in the EMR, India, Vietnam and Ghana [41–
44]. Rwanda, Cameroon, Gabon, Chad and the Congo highlight
the impact of payment mechanisms on access to medicines [45,46]
and socio-cultural factors affecting access as the major concerns
[46]. The Latin American Countries mention quality assurance as
an issue as well as high cost medicines and cost-containment
policies [47]. Regulation and community services are concerns
raised in Lao PDR [48]. Many countries also worry about access
to medicines for specific populations and disease conditions,
especially chronic non communicable conditions.
We found there was a mismatch between the available research
and identified policy concerns. Most research tended to be on
irrational prescribing with fewer studies related to the policy
concerns on regulation, pricing and supply management. The
Pakistan experience highlighted the need for trans-disciplinary
research to address identified policy concerns. Areas of critical
need are surveillance studies of drug availability, pricing, quality
Table 4. Prioritized Policy and Research Concerns through Stakeholders’ Roundtable.
Prioritized Policy Concerns: Research Concerns:
1 Too many registered products and low quality threshold for drug
company registration
1 Surveillance of policy, including decentralization, on prices, availability,
and quality
2 Post devolution need for independent drug regulation authority and
greater voice of all stakeholders
2 Best practice lessons learnt from LMICs for pricing policies, particularly
controlling availability of ‘orphan drugs’, market price variations and
unit cost price estimation
3 Lack of incentives to produce quality drugs 3 Investigating the success and failures of the essential medicines
programme and driving factors
4 Clear cut pricing formula not in place and decided pricing not easily
available nor enforced
4 Operational pilots for improved supply management including new
financing mechanisms, medicines information system, and pharmacist’s
role in decision making
5 Flat price control is counter productive resulting in disappearance of
low cost priced drugs
5 Mapping private licensed sector and ways to increase access through
private sector
6 Burden of medicine payment mainly on households 6 Examining consumer preferences for medicine use and underlying
drivers
7 Unnecessary, and often inappropriate prescriptions, by medical
practitioners
7 Transparency and availability of information related to medicine use
8 Little presence of therapeutic protocols & formularies in health facilities
9 Lack of public sharing of EDL, irregular updating and weak linkage with
morbidity data
10 Low availability of medicines in public sector at all tiers of health system
but improved availability with contracting –why?
11 Inadequate operational budget for medicine in public sector and
existing budget needs to be more efficiently managed
12 Need for centralized procurement in public sector and quality checks
13 Outdated logistics management systems
14 Weak hospital pharmacy across public and private sector
15 Proliferation of shadow pharmacies
16 Large and unregulated private sector and popularity of informal
providers and quacks
doi:10.1371/journal.pone.0063515.t004
Table 5. Prioritization of Policy & Research Concerns: Stakeholders’ Perceptions.
Dissemination and transparency of information in the fields of registration and licensing of medicines is the need of hour in Pakistan. The Ministry of Health needs to provide
publically list of registered and deregistered drugs.’’ (Stakeholder 2/21).
‘‘Optimal mix of pricing regulations is needed to reduce expenditure burden on households. Moreover continuous surveillance of impact of policies on availability, price and
affordability is needed.’’ (Stakeholder 6/21).
‘‘As far as prescribing is concerned, both private and public sector should follow the Essential Drug List. And there needs to be strict regulation and monitoring for it.’’
(Stakeholder 15/21).
‘‘Availability of essential medicines are compromised because of prescriptions written by the general physicians and specialists working in the private sector. For instance, if
you observe clinics in Lahore, Faisalabad, these (private) doctors have made pharmacies inside their clinics and prescribe only those drugs which are available with them
(Stakeholder 9/21).
doi:10.1371/journal.pone.0063515.t005
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and use, consumer behavioral research, interventional pilots
related to drug financing and supply management, and systematic
reviews of pricing interventions. There are similar gaps related to
access to medicine research in other LMICs. Medicine pricing and
availability surveys have been undertaken in a number of countries
[27] with WHO support but require periodic conduction in all
countries and use of standardized parameters. Interventional
research on drug access and use in developing countries is also
extremely limited in developing countries as also seen in Pakistan
[49,50]. In-depth understanding of consumer behavior and
experiences in relation to medicine use is another common
research gap in developing countries as is the case in Pakistan.
This study has three main strengths. First, the study provides
context relevant evidence from a developing country setting given
that access to essential medicine is a common issue across
developing countries and faces a dearth of evidence. Second, it
applies a health systems lens to essential medicine access which
offers the advantage of building important interconnections across
systems components to avoid fragmented, vertical and narrow
commodity based solutions to medicines access [4]. Finally, it
incorporates an iterative nationally driven prioritization of policy
and research concerns. According to the Working Group on
Priority Setting (2001) [51], locally driven research priorities and
use of qualitative process are considered more apt for health
systems priority setting rather than more quantitative close ended
scales used in disease ranking [52]. Although similar country level
priority setting exercises have lately been applied in the areas of
human resource [52] and health financing [53] in LMICs they
have not been previously applied to the area of access to essential
medicines. It also includes a multiple range of stakeholders in the
priority setting process as advocated for a systems perspective [54].
It also suffered from weaknesses. The desk review found studies of
varying study designs, sample sizes and quality, and could have
benefitted from standardized research and nationally representa-
tive samples [55]. The results may have been biased by purposive
selection of stakeholders however we tried to reduce bias by
including a broad range of stakeholders. Key informants had
difficulty in identifying research priorities for access to medicines,
and this may be due to a narrow bio-medical interpretation of
research or that not all policy concerns require a research action.
Similar difficulties in eliciting research concerns have been
observed in priority setting exercises in other health system areas
[56]. We found that the iterative roundtable process was more
effective in eliciting research priorities. Finally the conceptual
framework could have constrained the questions asked from key
informants however this was compensated our choice of a broad
and flexible framework, whereby topics not originally foreseen by
the framework but raised by informants were included (e.g. the
issue of devolution of services in Pakistan).
Conclusion
Pharmaceutical policy and health policy have traditionally co-
existed separately in developing countries with little effort to forge
linkages. The Pakistan experience shows that policy concerns
related to essential medicine access in Pakistan need integrated
responses across various components of the health systems, are
poorly addressed by existing evidence, and require an expanded
health systems research agenda. At the same time adequate steps
need to be taken to allow sustained dialogue between multiple
stakeholders and a continuous culture of research feeding into
evidence based policies.
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